We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Novel Therapies for Essential Tremor

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00018564
First Posted: July 5, 2001
Last Update Posted: January 21, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
VA Office of Research and Development
  Purpose
This clinical research program is designed to evaluate medications as new treatments for essential tremor. Essential tremor is a common condition with few available therapies.

Condition Intervention Phase
Essential Tremor Drug: treatments for essential tremor Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: Novel Therapies for Essential Tremor

Resource links provided by NLM:


Further study details as provided by VA Office of Research and Development:

Study Start Date: October 2000
Estimated Study Completion Date: September 2003
Detailed Description:
Each medication will be evaluated for effectiveness against tremor in a randomized, placebo-controlled, cross-over, double blind clinical research trial. Tremor will be assessed with accepted rating scales and accelerometry
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Diagnosis of essential tremor.
  2. Tremor rating scale score 3 or one or both upper extremities
  3. Unsatisfactory response to primidone or to propanolol
  4. Not taking tremor-inducing drug
  5. Able to comply with visits
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00018564


Locations
United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073
Sponsors and Collaborators
VA Office of Research and Development
Investigators
OverallOfficial: Fredricka Martin, Ph.D.
  More Information

ClinicalTrials.gov Identifier: NCT00018564     History of Changes
Other Study ID Numbers: NEUD-048-00S
First Submitted: July 3, 2001
First Posted: July 5, 2001
Last Update Posted: January 21, 2009
Last Verified: December 2004

Additional relevant MeSH terms:
Tremor
Essential Tremor
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Movement Disorders
Central Nervous System Diseases